BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu Y, Gruber KA, Smith DE. Characterization of the cellular transport mechanisms for the anti-cachexia candidate compound TCMCB07. J Cachexia Sarcopenia Muscle 2020;11:1677-87. [PMID: 32725770 DOI: 10.1002/jcsm.12602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Gruber KA, Ji RL, Gallazzi F, Jiang S, Van Doren SR, Tao YX, Newton Northup J. Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like Peptides. ACS Pharmacol Transl Sci 2022;5:344-61. [PMID: 35592439 DOI: 10.1021/acsptsci.1c00270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Axiak-Bechtel SM, Leach SB, Scholten DG, Newton-Northup JR, Johnson BJ, Durham HE, Gruber KA, Callahan MF. Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs. Pharmacol Res Perspect 2021;9:e00777. [PMID: 34014033 DOI: 10.1002/prp2.777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hu Y, Gruber KA, Smith DE. Characterization of the cellular transport mechanisms for the anti-cachexia candidate compound TCMCB07. J Cachexia Sarcopenia Muscle 2020;11:1677-87. [PMID: 32725770 DOI: 10.1002/jcsm.12602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]